Overview

• Orthofix Q3 net sales rose 5% yr/yr to $205.6 mln, beating analyst expectations

• Adjusted EBITDA for Q3 increased 28.2% yr/yr, beating analyst estimates

• Company narrowed full-year net sales guidance, raised low end of adjusted EBITDA guidance

Outlook

• Orthofix narrows 2025 net sales guidance to $810 mln-$814 mln

• Orthofix raises low end of 2025 adjusted EBITDA guidance to $84 mln-$86 mln

• Orthofix expects positive free cash flow for 2025, excluding M6 restructuring charges

Result Drivers

• SPINE FIXATION GROWTH - U.S. Spine Fixation net sales grew 8%, driven by 7D FLASH™ navigation technology

• BONE GROWTH THERAPIES - Bone Growth Therapies net sales increased by 6% due to effective cross-selling and leveraging access points

• ORTHOPEDICS LAUNCH - U.S. Orthopedics net sales grew 19%, aided by the launch of TrueLok™ Elevate

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for Orthofix Medical Inc is $23.00, about 30.2% above its November 3 closing price of $16.06

Press Release: ID:nBw3gn6Hza

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)